Clinical Trials Industry Dashboard 2022: Artificial Intelligence, Virtual Care and Chainsaw Activity in Q1 2022 –

DUBLIN–(BUSINESS WIRE)–The “Clinical Trials Industry Dashboard – Q1 2022 Update – Topic Search” report has been added to from offer.

Many companies included in the Clinical Trials Dashboard have announced partnerships in artificial intelligence (AI) since December 2021. Pfizer has announced partnerships in drug discovery and disease severity scoring , while Thermo Fisher Scientific announced that it is partnering with Medidata Acorn AI to optimize clinical outcomes. trials.

Merck KGaA collaborates with Unlearn.AI to accelerate late-stage trials using AI-powered digital twins. In the area of ​​virtual care, Takeda posted several jobs related to virtual trials and launched trials with virtual components in the first quarter of 2022, and AstraZeneca, Novo Nordisk and Otsuka were active in digital health agreements. Takeda released several blockchain-related jobs in the first quarter of 2022, and Dr. Reddy’s is partnering with universities to create a new blockchain solution.

Companies have also been active in ESG initiatives, driven in part by the Ukraine crisis.

Although there were no significant changes in environmental, social and governance (ESG) scores in the first quarter of 2022, several interesting events did occur. Samsung Bioepis published its first annual sustainability report, and in March 2022 Zydus Cadila announced that it would acquire a stake in AMP Energy Green Nine, a move in line with its commitment to improve its use of renewable energy.

AstraZeneca has announced that it is developing inhalers that use a more environmentally friendly propellant, HFO-1234ze, and it has also been reported that AstraZeneca China employees are being investigated for suspected fraud. to medical insurance. Many pharmaceutical companies have responded to the Ukrainian crisis by donating essential medicines, medical supplies and financial support to non-governmental organizations (NGOs).

Report Scope:

  • The Clinical Trials Thematic Scorecard report provides a comprehensive, top-down future outlook for the key players in the Clinical Trials industry over the next two to four years.

  • These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing and Blockchain

  • The dashboard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations ( CRO).

  • It is important to note that this dashboard is not an assessment of a company’s current performance within a theme, but a view of future performance based on current levels of activity and investment.

  • The methodology section contains information on the data sources used to generate the thematic scores for each company.

  • The dashboard is live on the PIC and will be updated quarterly

Key benefits of the report:

  • Identify key clinical trial topics for the next 2-4 years and learn about their impact on the market

  • Understand what key themes need to be addressed to drive the stock price

  • Understand which companies are best positioned to succeed in critical themes and why

  • Find out which companies have underinvested in key themes and are most vulnerable to disruption

  • Help companies adapt their strategy to anticipate and take advantage of these themes as they unfold

  • Help identify future winners and losers in drug development to inform partnership strategies

Main topics covered:

  • Summary

  • Pharmaceutical theme map

  • Clinical Trials Dashboard: Q1 2022 Key Updates

  • Company screen

  • Theme screen

  • Evaluation screen

  • Thematic research methodology

  • How Pharmaceutical Scores Are Generated

For more information on this report, visit

Source: Global Data

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Comments are closed.